lower schreef op 1 september 2016 14:53:
Triple, Shire is all langer bezig.
Drug Profile SHP 623
Alternative Names: rC1-INH - Shire; Recombinant-C1-esterase-Shire
adisinsight.springer.com/drugs/800043285SHP623 for prophylactic treatment of HAE
www.sec.gov/Archives/edgar/data/93640...SHP623 is a recombinant C1 inhibitor for the prophylactic treatment of HAE or other complement mediated diseases. SHP623 is intended to have a clinical profile similar to CINRYZE while providing manufacturing advantages and higher potency. In the fourth quarter of 2015, Shire received FDA approval of an IND to initiate a first-in-human study which is expected to be initiated in the first quarter of 2016.